Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity - PubMed (original) (raw)
Clinical Trial
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
Chao-Hua Chiu et al. Lung Cancer. 2005 Jan.
Abstract
Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer (NSCLC); however, its role in patients with brain metastases has not been clearly defined. We had conducted a prospective study to give gefitinib to NSCLC patients irrespective of their performance status (PS), number of prior treatment regimens and the presence of brain metastases. A total of 76 patients were enrolled. Fifty-seven patients had measurable lesions and the objective response rate was 33.3% (95% confidence interval [95% CI], 20.7-46.0%). For all enrolled patients, the disease control rate was 63.2% (95% CI, 52.1-74.3%) with a median progression-free survival of 5.0 months (95% CI, 3.6-6.5 months) and median overall survival 9.9 months (95% CI, 4.9-14.8 months). Twenty-one patients had simultaneously assessable intracranial lesions (ICLs) and extracranial lesions (ECLs), 17 of them (81.0%) showed comparable tumor response. There was no survival difference between the patients with and without metastatic brain disease. Most drug-related adverse events were mild. Intolerable toxicities happened in five patients, four of them were interstitial pneumonia (5.8%). Severity of skin toxicity was tightly associated with tumor response and patient survival (P = 0.007 and <0.001) and the association was consistent in the analysis using early toxicity profile (P = 0.033 and 0.001). In conclusion, gefitinib is active in patients with brain metastasis from NSCLC and tumor response is related to skin toxicity. It is feasible to conduct randomized trials to identify the role of gefitinib alone or in combination with other modality for treatment of NSCLC patients who have metastatic brain lesion(s).
Similar articles
- Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, Okada T, Hisamoto A, Tanimoto M. Hotta K, et al. Lung Cancer. 2004 Nov;46(2):255-61. doi: 10.1016/j.lungcan.2004.04.036. Lung Cancer. 2004. PMID: 15474674 Clinical Trial. - [Gefitinib is active in patients with brain metastasis from non-small cell lung cancer].
Tsai C, Chiu C, Liou J, Tsai P, Perng R. Tsai C, et al. Zhongguo Fei Ai Za Zhi. 2004 Aug 20;7(4):298-304. doi: 10.3779/j.issn.1009-3419.2004.04.07. Zhongguo Fei Ai Za Zhi. 2004. PMID: 21241546 Chinese. - Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, Takeda Y, Kimura H, Okada T, Yamaguchi T, Nakagawa M, Okumura Y, Maeda H, Ito M. Namba Y, et al. Clin Lung Cancer. 2004 Sep;6(2):123-8. doi: 10.3816/CLC.2004.n.026. Clin Lung Cancer. 2004. PMID: 15476598 Review. - A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Park K, Goto K. Park K, et al. Curr Med Res Opin. 2006 Mar;22(3):561-73. doi: 10.1185/030079906X89847. Curr Med Res Opin. 2006. PMID: 16574039 Review.
Cited by
- Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients.
Sugiura Y, Nemoto E, Kawai O, Ohkubo Y, Fusegawa H, Kaseda S. Sugiura Y, et al. Springerplus. 2013 Dec;2(1):22. doi: 10.1186/2193-1801-2-22. Epub 2013 Jan 23. Springerplus. 2013. PMID: 23420789 Free PMC article. - Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Kelly WJ, Shah NJ, Subramaniam DS. Kelly WJ, et al. Front Oncol. 2018 Jul 3;8:208. doi: 10.3389/fonc.2018.00208. eCollection 2018. Front Oncol. 2018. PMID: 30018881 Free PMC article. Review. - Comprehensive Review of Cranial Chordomas Using National Databases in the USA.
Hulou MM, Garcia CR, Slone SA, Dugan A, Lei F, Huang B, Pittman T, Villano JL. Hulou MM, et al. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):e149-e159. doi: 10.1016/j.clon.2019.06.004. Epub 2019 Jul 11. Clin Oncol (R Coll Radiol). 2019. PMID: 31303332 Free PMC article. Review. - Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q. Zhang Q, et al. Thorac Cancer. 2016 Nov;7(6):648-654. doi: 10.1111/1759-7714.12379. Epub 2016 Sep 1. Thorac Cancer. 2016. PMID: 27755835 Free PMC article. - EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV. Eichler AF, et al. Neuro Oncol. 2010 Nov;12(11):1193-9. doi: 10.1093/neuonc/noq076. Epub 2010 Jul 13. Neuro Oncol. 2010. PMID: 20627894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical